Pipeline

1) Indi Molecular is pursuing a hybrid strategy that emphasizes strategic partnerships focused on oncology therapeutics and molecular imaging -- a theranostic approach to therapy. We focus on high value, high need therapeutic indications including Ovarian Cancer and Pancreatic Cancer.

2) PCC’s unsurpassed chemical stability, high chemical selectivity, speed of preparation, low production cost and exact chemical composition confer distinct advantages in these fields that monoclonal antibodies cannot match. Applications range from displacing antibody-dominated techniques in molecular in vivo imaging and targeted therapeutics to major advances in both biological tools and in vitro diagnostics settings.

3) The company has a successful partnering history that includes the California Institute of Technology, GE Healthcare, the Gates Foundation and the United States Department of Defense.